---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-057945"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T19:59:55.748785+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# iBio appoints Dr. Elizabeth Stoner to board, replaces Eef Schimmelpennink

## Summary
- Dr. Stoner appointed as Class II director and Compensation Committee member, effective May 7, 2026.
- She brings 35+ years pharma R&D experience; currently Entrepreneur Partner at MPM BioImpact.
- Eef Schimmelpennink resigned immediately; departure not due to any disagreement with the Company.
- Standard non-employee director compensation: $40k annual board fee, $7.5k committee fee, option grant.
- CEO cites upcoming first human clinical trial for obesity and pulmonary hypertension therapies.

## SEC filing metadata
- accession: 0001104659-26-057945
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000110465926057945/0001104659-26-057945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000110465926057945/ibio-20260507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-057945
- JSON: https://secwatch.observer/filing/0001104659-26-057945.json
- Plain text: https://secwatch.observer/filing/0001104659-26-057945.txt

## Key facts
- Executive change
  Evert Schimmelpennink resigned as Member of the Board at iBio, Inc..
  - Action: resigned
  - Role: Member of the Board
  source text: On May 7, 2026, Evert Schimmelpennink, a member of the Board, notified the Company of his decision to resign from the Board, including from his position as a member of the Compensation Committee of the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420720/000110465926057945/0001104659-26-057945-index.htm
- Executive change
  Dr. Elizabeth Stoner was appointed as Class II director at iBio, Inc..
  - Action: appointed
  - Role: Class II director
  source text: On May 7, 2026, the Board of Directors (the “Board”) of iBio, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Elizabeth Stoner, M.D., M.S., to serve as a Class II director of the Company, effective May 7, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420720/000110465926057945/0001104659-26-057945-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.